Ir para o conteúdo principal

Neurosense Therapeutics (NASDAQ: NRSN) — Perfil da empresa, notícias e dados financeiros

Logo de Neurosense Therapeutics
NRSN Neurosense Therapeutics
Neurosense Therapeutics primary media
Perfil da empresa

Neurosense Therapeutics

Neurosense Therapeutics (NASDAQ:NRSN) focuses on developing treatments for neurodegenerative diseases, particularly those without current effective therapies. Their work revolves around pioneering approaches to combat conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease, aiming to significantly improve the quality of life for patients. Projects include innovative drug development and clinical trials designed to test the efficacy and safety of new therapies. Neurosense's objectives are deeply rooted in the pursuit of breakthroughs that can halt or reverse the progression of debilitating neurological conditions, demonstrating their commitment to advancing medical science and patient care. Through their dedicated research and development efforts, Neurosense strives to address some of the most challenging aspects of neurodegenerative disease treatment.

Resumo

Public USParticipação acionária
2017Ano de fundação
14Funcionários
Rehovot, IsraelSede
Carregando mapa...
Presença global

Operações

Todos os locais
Reẖovot, IL

Produtos e/ou serviços de Neurosense Therapeutics

  • Development of PrimeC, a novel formulation aimed at treating amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
  • Research into combination therapies for prolonging the life of neurons in neurodegenerative conditions.
  • Innovative drug development pipeline focused on addressing unmet needs in rare neurological disorders.
  • Creation of proprietary technologies for enhancing drug delivery across the blood-brain barrier.
  • Advanced screening platforms for discovering novel neuroprotective agents.
  • Strategic collaborations with leading pharmaceutical companies for accelerating drug development and commercialization.

equipe executiva do Neurosense Therapeutics

  • Alon Ben-NoonCo-Founder, CEO & Director
  • Or EisenbergChief Financial Officer
  • Niva Russek-BlumChief Technology Officer

Comunicados recentes

O que a Neurosense Therapeutics (NRSN) comunicou ao mercado, do mais recente para o mais antigo.

Principais indicadores financeiros

Resultados divulgados pela Neurosense Therapeutics, em USD.

Cap. de mercado
3,1 mi
Receita (TTM)
0
P/L
—
LPA (diluído, TTM)
-47.1
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Neurosense Therapeutics
Fim do ano fiscalReceitaResultado operacionalLucro líquido
0-11,1 mi-11,1 mi
0-9,9 mi-10,2 mi
0-12 mi-10,1 mi
0-13,6 mi-12,3 mi